Market Summary
USD136.82+2.79
Market Closed2.08%
A Stock Price
A RSI Chart
A Valuation
A Price/Sales (Trailing)
A Profitability
A Fundamentals
A Revenue
A Earnings
Price Action
52 Week Range
112.32159.59
(Low)(High)
Last 7 days
-4.9%
Last 30 days
-13.3%
Last 90 days
-11.2%
Trailing 12 Months
3.2%
A Financial Health
A Investor Care
Peers (Alternatives to Agilent Tech)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
A | 40.4B | 6.8B | -13.31% | 3.22% | 32.19 | 5.89 | 8.37% | 3.64% |
ILMN | 35.5B | 4.6B | 5.65% | -27.02% | -8.07 | 7.75 | 1.28% | -677.95% |
MTD | 32.5B | 3.9B | -7.42% | 9.05% | 37.3 | 8.3 | 5.43% | 13.46% |
WAT | 18.2B | 3.0B | -10.97% | -4.88% | 25.66 | 6.11 | 6.68% | 2.15% |
PKI | 15.9B | 3.3B | -11.65% | -27.44% | 27.98 | 4.81 | -34.64% | -39.65% |
| MID-CAP | ||||||||
| SMALL-CAP | ||||||||
PACB | 2.0B | 128.3M | -11.70% | -1.09% | -6.37 | 15.61 | -1.69% | -73.40% |
ADPT | 1.2B | 185.3M | -5.41% | -23.53% | -6 | 6.49 | 20.06% | 3.42% |
QTRX | 450.3M | 105.5M | -12.44% | -50.56% | -4.66 | 4.27 | -4.55% | -67.63% |
NSTG | 405.5M | 127.3M | -23.43% | -69.17% | -2.54 | 3.19 | -12.28% | -38.43% |
BNGO | 341.8M | 27.8M | -23.57% | -31.43% | -2.58 | 12.29 | 54.62% | -83.06% |
CDXS | 271.1M | 138.6M | -29.13% | -76.08% | -8.07 | 1.96 | 32.30% | -57.86% |
PSNL | 135.5M | 65.0M | -20.46% | -63.49% | -1.2 | 2.08 | -23.92% | -73.73% |
HBIO | 117.4M | 113.3M | -15.92% | -55.18% | -12.34 | 1.04 | -4.68% | -3204.17% |
CSBR | 54.2M | 54.1M | -0.24% | -45.98% | 502.17 | 1 | 21.80% | -72.38% |
Financials for Agilent Tech
| Income Statement (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Revenue | 2.8% | 6,848 | 6,659 | 6,527 | 6,445 | 6,319 |
| S&GA Expenses | 2.1% | 1,637 | 1,604 | 1,595 | 1,629 | 1,619 |
| R&D Expenses | 0.6% | 467 | 464 | 461 | 455 | 441 |
| Costs and Expenses | 2.2% | 5,230 | 5,117 | 5,060 | 5,050 | 4,972 |
| EBITDA | -0.1% | 1,905 | 1,907 | 1,843 | - | - |
| EBITDA Margin | -2.9% | 0.28* | 0.29* | 0.28* | - | - |
| Earnings Before Taxes | 0.5% | 1,504 | 1,497 | 1,427 | 1,367 | 1,360 |
| EBT Margin | -2.3% | 0.22* | 0.22* | 0.22* | - | - |
| Interest Expenses | 2.4% | 84.00 | 82.00 | 84.00 | 83.00 | 81.00 |
| Net Income | -5.6% | 1,254 | 1,328 | 1,263 | 1,205 | 1,210 |
| Net Income Margin | -8.2% | 0.18* | 0.20* | 0.19* | - | - |
| Free Cahsflow | -0.1% | 1,021 | 1,022 | 1,058 | - | - |
| Balance Sheet | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Assets | 0.5% | 10,532 | 10,484 | 10,455 | 10,327 | 10,705 |
| Current Assets | 2.4% | 3,778 | 3,690 | 3,643 | 3,474 | 3,799 |
| Cash Equivalents | -1.7% | 1,053 | 1,071 | 1,186 | 1,113 | 1,484 |
| Inventory | 2.8% | 1,038 | 1,010 | 937 | 879 | 830 |
| Net PPE | 4.4% | 1,100 | 1,054 | 1,010 | 974 | 945 |
| Goodwill | 0.1% | 3,952 | 3,948 | 3,956 | 3,964 | 3,975 |
| Liabilities | -3.1% | 5,227 | 5,393 | 5,333 | 5,173 | 5,316 |
| Current Liabilities | -2.2% | 1,861 | 1,902 | 1,813 | 1,584 | 1,708 |
| . Short Term Borrowings | -80.0% | 36.00 | 180 | 175 | - | - |
| Long Term Debt | 0.0% | 2,733 | 2,732 | 2,729 | - | - |
| LT Debt, Non Current | 0% | 2,730 | 2,730 | 2,729 | - | - |
| Shareholder's Equity | 4.2% | 5,305 | 5,091 | 5,122 | 5,154 | 5,389 |
| Retained Earnings | 133.1% | 324 | 139 | 160 | 159 | 348 |
| Additional Paid-In Capital | 0.3% | 5,325 | 5,311 | 5,292 | 5,290 | 5,320 |
| Shares Outstanding | -0.3% | 295 | 296 | 299 | 300 | 302 |
| Cashflow (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Cashflow From Operations | 0.5% | 1,312 | 1,305 | 1,313 | 1,502 | 1,485 |
| Share Based Compensation | 3.3% | 125 | 121 | 115 | 114 | 110 |
| Cashflow From Investing | -17.8% | -338 | -287 | -275 | -786 | -749 |
| Cashflow From Financing | -1.3% | -1,372 | -1,355 | -1,215 | -926 | -696 |
| Dividend Payments | 5.9% | 250 | 236 | - | - | - |
| Buy Backs | -0.1% | 1,139 | 1,140 | 930 | 891 | 788 |
Risks for A
What is the probability of a big loss on A?
39.6%
Probability that Agilent Tech stock will be more than 20% underwater in next one year
11.5%
Probability that Agilent Tech stock will be more than 30% underwater in next one year.
0%
Probability that Agilent Tech stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does A drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Agilent Tech was unfortunately bought at previous high price.
Drawdowns
Returns for A
Cumulative Returns on A
16.7%
10-Year Cumulative Returns
20.2%
7-Year Cumulative Returns
14.7%
5-Year Cumulative Returns
25.4%
3-Year Cumulative Returns
What are the long-term rolling returns for A?
FIve years rolling returns for Agilent Tech.
Annualized Returns
Which funds bought or sold A recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-03-15 | B. Riley Wealth Advisors, Inc. | reduced | -43.04 | -184,861 | 434,139 | 0.01% |
2023-03-10 | MATHER GROUP, LLC. | added | 9.38 | 359,680 | 1,399,680 | 0.03% |
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | added | 22.85 | 70,395,200 | 207,743,000 | 0.23% |
2023-03-06 | BIRMINGHAM CAPITAL MANAGEMENT CO INC/AL | unchanged | - | 147,656 | 788,656 | 0.30% |
2023-03-06 | Rockefeller Capital Management L.P. | added | 19.65 | 370,000 | 1,151,000 | 0.01% |
2023-03-03 | TIAA, FSB | added | 0.8 | 128,256 | 660,256 | -% |
2023-03-02 | LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA | new | - | 866,473 | 866,473 | 0.01% |
2023-02-28 | CYPRESS ASSET MANAGEMENT INC/TX | unchanged | - | 119,012 | 636,012 | 0.23% |
2023-02-28 | Voya Investment Management LLC | reduced | -10.5 | 10,070,500 | 108,935,000 | 0.15% |
2023-02-27 | CASCADE INVESTMENT GROUP, INC. | new | - | 574,791 | 574,791 | 0.60% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Agilent Tech News
Schedule 13G FIlings of Agilent Tech
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 14, 2023 | price t rowe associates inc /md/ | 2.6% | 7,707,066 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 8.53% | 25,250,988 | SC 13G/A | |
| Jan 26, 2023 | blackrock inc. | 10.9% | 32,309,878 | SC 13G/A | |
| Jan 20, 2023 | blackrock inc. | 10.9% | 32,309,878 | SC 13G/A | |
| Apr 08, 2022 | blackrock inc. | 10.0% | 30,082,335 | SC 13G/A | |
| Feb 14, 2022 | price t rowe associates inc /md/ | 7.1% | 21,689,105 | SC 13G/A | |
| Feb 09, 2022 | vanguard group inc | 8.04% | 24,269,735 | SC 13G/A | |
| Feb 03, 2022 | blackrock inc. | 9.7% | 29,352,219 | SC 13G/A | |
| Feb 16, 2021 | price t rowe associates inc /md/ | 7.6% | 23,512,823 | SC 13G/A | |
| Feb 10, 2021 | vanguard group inc | 7.76% | 23,804,938 | SC 13G/A |
A Fair Value
Agilent Tech fair value in different scenarios
The table shows the Fair Value estimates for Agilent Tech for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
| Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
|---|---|---|---|---|---|
| Very Low Inflation | 64.63 -52.76% | 78.57 -42.57% | 103.33 -24.48% | 133.55 -2.39% | 169.19 23.66% |
| Current Inflation | 59.19 -56.74% | 70.91 -48.17% | 91.45 -33.16% | 116.54 -14.82% | 146.16 6.83% |
| Very High Inflation | 52.53 -61.61% | 61.73 -54.88% | 77.55 -43.32% | 96.94 -29.15% | 119.90 -12.37% |
Historical Agilent Tech Fair Value Estimates
Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price
Recent SEC filings of Agilent Tech
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Mar 16, 2023 | 4 | Insider Trading | |
| Mar 03, 2023 | 10-Q | Quarterly Report | |
| Feb 28, 2023 | 8-K | Current Report | |
| Feb 22, 2023 | DEFA14A | DEFA14A | |
| Feb 14, 2023 | SC 13G/A | Major Ownership Report | |
| Feb 09, 2023 | SC 13G/A | Major Ownership Report | |
| Feb 03, 2023 | ARS | ARS | |
| Feb 03, 2023 | DEF 14A | DEF 14A | |
| Jan 26, 2023 | SC 13G/A | Major Ownership Report | |
| Jan 20, 2023 | SC 13G/A | Major Ownership Report |
Latest Insider Trading transactions for A
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2022-12-14 | Ancher-Jensen Henrik | sold | -4,595,510 | 155 | -29,500 | sr vice president |
2022-12-13 | MCDONNELL PADRAIG | sold | -107,520 | 160 | -672 | sr. vice president |
2022-12-13 | Grau Dominique | sold | -636,800 | 159 | -4,000 | senior vice president |
2022-12-06 | KOH BOON HWEE | sold | -1,978,690 | 152 | -13,000 | - |
2022-12-01 | Thaysen Jacob | sold | -503,528 | 155 | -3,235 | sr. vice president |
2022-11-30 | Thaysen Jacob | sold | -1,499,910 | 154 | -9,700 | sr. vice president |
2022-11-23 | Gonsalves Rodney | gifted | -143,543 | 155 | -924 | v.p., corporate controller |
2022-11-23 | Gonsalves Rodney | sold | -723,831 | 156 | -4,634 | v.p., corporate controller |
2022-11-23 | Gonsalves Rodney | gifted | 143,543 | 155 | 924 | v.p., corporate controller |
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, next generation sequencing, target enrichment and genetic data management, and interpretation support software; and produces synthesized oligonucleotide. It also offers immunohistochemistry in situ hybridization, and hematoxylin and eosin staining and special staining; consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops liquid-based pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.
A Income Statement
2023-01-31CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (Unaudited) - USD ($) shares in Millions, $ in Millions | 3 Months Ended | |
|---|---|---|
Jan. 31, 2023 | Jan. 31, 2022 | |
| Net revenue: | ||
| Net revenue | $ 1,756 | $ 1,674 |
| Costs and expenses: | ||
| Cost of revenue | 788 | 764 |
| Research and development | 123 | 117 |
| Selling, general and administrative | 419 | 417 |
| Total costs and expenses | 1,330 | 1,298 |
| Income from operations | 426 | 376 |
| Interest income | 9 | 1 |
| Interest expense | (25) | (21) |
| Other income (expense), net | 0 | (37) |
| Income before taxes | 410 | 319 |
| Provision for income taxes | 58 | 36 |
| Net income | $ 352 | $ 283 |
| Net income per share | ||
| Basic | $ 1.19 | $ 0.94 |
| Diluted | $ 1.19 | $ 0.93 |
| Weighted average shares used in computing net income per share: | ||
| Basic | 296 | 301 |
| Diluted | 297 | 303 |
| Product | ||
| Net revenue: | ||
| Net revenue | $ 1,323 | $ 1,263 |
| Costs and expenses: | ||
| Cost of revenue | 556 | 545 |
| Service and Other | ||
| Net revenue: | ||
| Net revenue | 433 | 411 |
| Costs and expenses: | ||
| Cost of revenue | $ 232 | $ 219 |
A Balance Sheet
2023-01-31CONDENSED CONSOLIDATED BALANCE SHEET (Unaudited) - USD ($) $ in Millions | Jan. 31, 2023 | Oct. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 1,250 | $ 1,053 |
| Accounts receivable, net | 1,459 | 1,405 |
| Inventory | 1,111 | 1,038 |
| Other current assets | 258 | 282 |
| Total current assets | 4,078 | 3,778 |
| Property, plant and equipment, net | 1,147 | 1,100 |
| Goodwill | 3,983 | 3,952 |
| Other intangible assets, net | 810 | 821 |
| Long-term investments | 188 | 195 |
| Other assets | 713 | 686 |
| Total assets | 10,919 | 10,532 |
| Current liabilities: | ||
| Accounts payable | 540 | 580 |
| Employee compensation and benefits | 296 | 455 |
| Deferred revenue | 521 | 461 |
| Short-term debt | 238 | 36 |
| Other accrued liabilities | 341 | 329 |
| Total current liabilities | 1,936 | 1,861 |
| Long-term debt | 2,733 | 2,733 |
| Retirement and post-retirement benefits | 99 | 97 |
| Other long-term liabilities | 542 | 536 |
| Total liabilities | 5,310 | 5,227 |
| Commitments and Contingencies (Note 9 and 12) | ||
| Stockholders' equity: | ||
| Preferred stock; $0.01 par value; 125 million shares authorized; none issued and outstanding | 0 | 0 |
| Common stock; $0.01 par value; 2 billion shares authorized; 296 million shares at January 31, 2023 and 295 million shares at October 31, 2022, issued and outstanding | 3 | 3 |
| Additional paid-in-capital | 5,345 | 5,325 |
| Retained earnings | 541 | 324 |
| Accumulated other comprehensive loss | (280) | (347) |
| Total stockholder's equity | 5,609 | 5,305 |
| Total liabilities and equity | $ 10,919 | $ 10,532 |